RxDoctor Payments Data

Marvin Tark

Interventional Pain Medicine · Marietta, GANPI 1548373210

Payments from drug & device makers

What this record shows

Modernatx, Inc. accounts for 82.6% of it on its own, with 12 other manufacturers making up the rest. 2023 is the largest year on record at $1,406, 5.7 times the $245 reported in 2019. That places this record below the midpoint for interventional pain medicine clinicians in GA, where the typical reported total is $4,377.

$1,703in general payments, 2019–2025

Across 27 payments — averaging $63.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Modernatx, Inc.$1K
  • Pfizer$55
  • Pacira Therapeutics, Inc.$36
  • Novartis$34
  • Nevro Corp.$31
  • Daiichi Sankyo Inc.$28
  • plus $112 from 7 others
$3,636,502in research payments, 2019–2025

Across 147 payments — averaging $24,738 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Modernatx, Inc.$3M
  • Regeneron$339K
  • Acadia Pharmaceuticals Inc$83K
  • GRT US Holding, Inc.$46K
  • Lexicon Pharmaceuticals, Inc.$42K
  • Pfizer$39K
  • plus $46K from 4 others

What the payments were for

  • Travel & lodging$89953%
  • Food & beverage$80447%

General payments by program year

19
20
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,703 in reported general payments places this provider in the 30th percentile of 129 interventional pain medicine providers in Georgia.

See all interventional pain medicine providers in Georgia

Other interventional pain medicine in Marietta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →